[A21-30] Semaglutide (type 2 diabetes mellitus) - Addendum to Commission A20-93
Last updated 15.04.2021
Project no.:
A21-30
Commission:
Commission awarded on 10.03.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Type 2 diabetes mellitus in adults
Result of dossier assessment unchanged after addendum:
Monotherapy in adults in whom diet and exercise alone do not provide adequate glycaemic control and the use of metformin is considered inappropriate due to intolerance or contraindications: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with 1 other blood-glucose lowering drug (except insulin) do not provide adequate glycaemic control: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with at least 2 other blood-glucose lowering drugs (except insulin) do not provide adequate glycaemic control: added benefit not proven.
Combination therapy in adults in whom diet and exercise and treatment with insulin (with or without 1 other blood-glucose lowering drug) do not provide adequate glycaemic control: added benefit not proven.
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A20-93 | Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2021.04.15 A G-BA decision was published.